Evotec to tackle Huntington’s disease

Evotec AG has reinforced its position in drug discovery with a new agreement to identify potential treatments for Huntington’s disease. The agreement comes at a time when the Germany-based company is narrowing its strategic focus after setbacks more than a year ago with two clinical-stage products

Location